Table 2 Clinical characteristics and risk factors associated with bloodstream infection caused by carbapenem-resistant Acinetobacter spp.

Male sex

11 (45.8)

11 (68.8)

0.154

Age

median (range)

16 (1–62)

27.5 (1–54)

0.404

≥ 45

6 (25.0)

5 (31.3)

0.728

Underlying diseases

VSAA

3 (12.5)

6 (37.5)

0.120

ALL

9 (37.5)

2 (12.5)

0.148

AML

10 (41.7)

7 (43.8)

0.896

MDS

1 (4.2)

1 (6.3)

1.000

DCLCB

1 (4.2)

0 (0.0)

1.000

Diabetes

1 (4.2)

2 (12.5)

0.553

Accompanying symptoms

Respiratory failure

3 (12.5)

6 (37.5)

0.120

Cardiac dysfunction

5 (20.8)

8 (50.0)

0.054

Severe sepsis/septic shock

4 (16.7)

6 (37.5)

0.159

Hypoproteinemia

8 (34.8) ^a

11 (68.8) ^a

0.037*

5.708 (0.823–39.566)

0.078

Carbapenem-resistantAcinetobacterspp. colonization

0 (0.0%)

10 (62.5)

< 0.001*

11.949 (1.799–79.363)

0.010*

Length of hospital stay before BSI

16 (4–28)

14 (5–24)

0.723

Interventions within 30 days

Central venous catheterization

22 (91.7)

12 (75.0)

0.195

Intravenous glucocorticoid

14 (58.3)

11 (68.8)

0.505

Immunosuppressive therapy

21 (87.5)

12 (75.0)

0.407

Chemotherapy

17 (70.8)

8 (50.0)

0.182

ATG/ALG

1 (4.2)

2 (12.5)

0.553

HSCT

0 (0.0)

2 (12.5)

0.154

Laboratory results

Unresolved neutropenia before infection

8 (36.4) ^b

5 (33.3) ^b

0.850

Unresolved neutropenia after infection

11 (45.8)

10 (62.5)

0.301

Time of antibiotic treatment after BSI

11 (5–16)

20.5 (6–40)

0.220

Antimicrobial exposure at the onset of BSI

8 (33.3)

13 (81.3)

0.003*

Previous antibiotic use

18 (75.0)

16 (100.0)

0.064

BLICs

9 (37.5)

9 (56.3)

0.243

Broad-spectrum cephalosporins

1 (4.2)

4 (25.0)

0.138

Carbapenems

5 (20.8)

12 (75.0)

0.001*

6.927 (1.125–42.638)

0.037*

Tigecycline

1 (4.2)

2 (12.5)

0.553

Trimethoprim-sulfamethoxazole

4 (16.7)

1 (6.3)

0.631

Multidrug-resistant

3 (12.5)

16 (100.0)

< 0.001*

Inappropriate empirical therapy

1 (4.2)

11 (68.8)

< 0.001*